Pharmaco - Articles

PharmiWeb Solutions are looking for a Client Project Manager, to manage the implementation of innovative web and software developments for our blue chip customer base.
PharmiWeb Solutions - publisher of PharmiWeb.com - is one of the UK's leading providers of web based solutions to the pharmaceutical sector. In fact we're so good that we this year we have been shortlisted for the UK AOP Best Business Online Publisher 2007 Award. And we're expanding too. This is where you come in. We are looking for a Client Project Manager, to manage the implementation of innovative web and software developments for our blue chip customer base. If you are keen to join a young, entrepreneurial, fast growth organisation, we'd like to hear from you. You'll need a blend of web, pharma, marketing and project…

Two things; firstly among all of the great business concepts of the last few decades the franchise model has always surfaced to the very top. Secondly, over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
Firstly, the places to park new concepts; the current, ever-expanding construction phases in Dubai, UAE, GCC and all over Asia, provide a highly fertile ground for such concepts to nestle in, a home in the newly designed and creatively appointed decors, so that the cute new concepts with the most lavish and appealing ideas would flourish. The combination of creative concepts blended w…

Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award. We enjoy punching above our weight, and relish the fact that we are up against major international p…

Merck’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies – Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this year’s American Diabetes Association meeting in Chicago.
Merck’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies – Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this year’s American Diabetes Association meeting in Chicago. At least eight other companies including Servier, P…

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects Treatment of mood disturbance in bipolar disorder is undergoing a paradigm shift. Traditionally, drug therapy has been focussed on efficacy in acute mania or depression. Now psychiatrists are realising the need to evaluate drug treatments from other perspectives, Their full effects as acute and mood-stabilising agents, side effect profiles, effects on neurocognitive functioning, quality of life, and on psychosocial functioning, are also important when considering therapy. Bipolar disorder, the condition where mood swings…

First medicine shown to extend survival of previously untreated lung cancer patients beyond one year.
Basel, July 20, 2007. Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the first-line use of Avastin in the treatment of the most common form of lung cancer, in combination with platinum-based chemotherapy. The CHMP’s decision is based on data from the pivotal US (E4599) study and another phase III Avastin in Lung (AVAiL) study which together demonstrate that Avastin is effective in combination with a broad chemotherapy range. Lung cancer is responsible for over 3,000 deaths per day world-wide1 and non-small cell lung cancer (NSCLC) is the most common form of the disease accounting for more than 80 perc…

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager. Tony has 20+ years of Recruitment Experience and joins with the brief to assist with Barrington James’ ambitious growth plans across the UK and Europe.…

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal…

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
But this time, is he going too far? On June 28th, Paul will set off from Hampton Court, London, on a 3 day, 600km stage race from London to Paris (the L2P). Other riders will include top 1980s pro cyclist Sean Kelly, and European Classics star, Johann Museuw. This will ensure a pace designed to make the lesser rider suffer. So why bother? Well, the ride is designed as a sponsorship event to benefit three Children’s charities This year L2P will be supporting three charities: Morning Star Children’s Centre, a day care facility for babies and young children, often orphans, who are infected with HIV/AI…

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first-line therapy for b…

In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference. Four students from Nigeria, Ghana, Liberia and Cameroon will receive the bursaries from Lhasa Limited to fund their journey to the Main Campus of Nnamdi Azikiwe University Awka, Nigeria. The conference runs from June 11 to June 14 with the theme; Integrating new technologies in drug development. Dr. Chudy Nduaka, President and Board Chairman of the Africa Education Initi…

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
BENEFiT study shows Tracleer (bosentan) improves haemodynamics in CTEPH patients refused surgery Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial prese…

In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
So you want to contract staff… what do you need to consider? In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce…

With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
What’s Up (Junior) Doc? London, May 22 2007 With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS…

Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
The Newspaper Cemetery Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket. The Children of the Millennium Historians will reg…

The biogenerics industry consolidates with Indian players emerging in Western countries; pegylation, protein engineering, drug delivery and oral small molecules feed the pipeline of next generation competitors of therapeutic proteins
BARCELONA, Spain | April 24, 2007 | The Business Intelligence firm La Merie S.L. reported today that the consolidation process in the biogenerics industry has commenced after first approvals of biogeneric human growth hormone products in the US and the EU and first filings of biogeneric erythropoietin and insulin in the EU. Smaller biogeneric companies have been taken over by generic players from India and Eastern Europe . Large generic and hospital specialist companies have entered the field by acquisition and licensing deals. Apart from biogenerics, the US$…

The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care.
IDF Europe, Brussels, April 17th 2007, 12.01AM: The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care. They are inadequately controlled on oral antidiabetics but under a false sense of security about the severity of their disease.1 The survey revealed that over three-quarters of patients across Europe wrongly believe their poorly controlled condition is well managed and almost half believe that they have ‘mild’ diabetes.1 The Choose C…

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
In the past few days we have seen Merck and Schering-Plough announce results ahead of expectations, and now Wyeth joins the club too, with Q1 revenues up by 11%, earnings per share up 12%, and its Pharmaceuticals, Consumer Healthcare and Animal Health segments all hitting double-digit net revenue growth. Commenting on the results, Robert Essner, Chairman and Chief Executive Officer said “Wyeth’s financial performance in the 2007 first quarter was again outstanding. On top of that, the Company added momentum to our new product pipeline by successfully completing a number of important clinical trials for Pristiq for vasomotor symptoms and depressio…

The Sales Technology & CRM Webinar will take place at 15.00 GMT/10.00 EST, 24th May 2007
The Sales Technology & CRM Webinar will take place at 15.00 GMT/10.00 EST, 24th May 2007 11th April 2007, London, UK – EyeforPharma, world renowned leader in providing business strategy information and conferences for the pharmaceutical industry, has announced dates for a new concept in short interactive webinar forums to enable participants a quick and cost effective route to keep in touch with trends, analysis and major topics in the Pharma Industry. Under the banner of Sales Force Effectiveness the latest of the webinar events will take place on 24th May 2007 15.00 GMT/10.00 EST covering the topics of Sales Technology and CRM, allowing registered attendees a ‘power hour’ in which to discuss…

SYDNEY, N.S.W., 2 Mar 2007 – The recently released GenericsWeb Pipeline Developer patent report for Levitra® (Vardenafil) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product’s lifecycle.
SYDNEY, N.S.W., 2 Mar 2007 – The recently released GenericsWeb Pipeline Developer patent report for Levitra® (Vardenafil) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product’s lifecycle. Levitra®, launched by Bayer in 2003, is closely related to Pfizer’s blockbuster product Viagra® (Sildenafil), and is indicated for the treatment of erectile dysfunction. According to Bayer, sales of Levitra® were €260 million in 2005. L…